NAOV vs. BBLG, SIENQ, POAI, HSCS, ACON, NUWE, CMND, SLRX, THMO, and NTBL
Should you be buying NanoVibronix stock or one of its competitors? The main competitors of NanoVibronix include Bone Biologics (BBLG), Sientra (SIENQ), Predictive Oncology (POAI), Heart Test Laboratories (HSCS), Aclarion (ACON), Nuwellis (NUWE), Clearmind Medicine (CMND), Salarius Pharmaceuticals (SLRX), ThermoGenesis (THMO), and Notable Labs (NTBL). These companies are all part of the "medical" sector.
Bone Biologics (NASDAQ:BBLG) and NanoVibronix (NASDAQ:NAOV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their community ranking, risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.
In the previous week, Bone Biologics and Bone Biologics both had 1 articles in the media. NanoVibronix's average media sentiment score of 0.50 beat Bone Biologics' score of 0.34 indicating that Bone Biologics is being referred to more favorably in the media.
NanoVibronix received 71 more outperform votes than Bone Biologics when rated by MarketBeat users.
34.3% of Bone Biologics shares are held by institutional investors. Comparatively, 16.4% of NanoVibronix shares are held by institutional investors. 13.0% of Bone Biologics shares are held by company insiders. Comparatively, 3.6% of NanoVibronix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Bone Biologics has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, NanoVibronix has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500.
NanoVibronix has higher revenue and earnings than Bone Biologics. NanoVibronix is trading at a lower price-to-earnings ratio than Bone Biologics, indicating that it is currently the more affordable of the two stocks.
Bone Biologics has a net margin of 0.00% compared to Bone Biologics' net margin of -162.55%. Bone Biologics' return on equity of -123.23% beat NanoVibronix's return on equity.
Summary
NanoVibronix beats Bone Biologics on 7 of the 12 factors compared between the two stocks.
Get NanoVibronix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAOV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAOV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NanoVibronix Competitors List
Related Companies and Tools
